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Strengths and limitations of this study
 ► Strengths of the data source analysed in this study 
include comprehensive, national, data collection 
and the ability to match treatment with outcomes, 
including by the laterality of intervention, over time.
 ► This is the largest cohort of patients undergoing 
arthroscopic chondroplasty that has been reported, 
with strict inclusion criteria, excluding patients with 
a history of previous surgery to the same knee and 
those undergoing simultaneous ligament recon-
struction or microfracture.
 ► All studies of this design rely on coding accuracy 
and some coding errors are inevitable; although out-
comes were stratified by a range of patient factors, 
unmeasured potential confounders include body 
mass index, limb alignment, baseline radiographic 
status.
 ► Knee arthroplasty is an end- stage outcome and 
will underestimate the true burden and severity of 
symptomatic osteoarthritis in this population.
 ► The outcome had these patients not undergone ar-
throscopic chondroplasty remains unknown.
AbStrACt
Objective The purpose of this study was to analyse the 
rate of knee arthroplasty in the population of patients 
with a history of arthroscopic chondroplasty of the 
knee, in England, over 10 years, with comparison to 
general population data for patients without a history of 
chondroplasty.
Design Retrospective cohort study.
Setting English Hospital Episode Statistics (HES) data.
Participants and interventions Patients undergoing 
arthroscopic chondroplasty in England between 2007/2008 
and 2016/2017 were identified. Patients undergoing 
previous arthroscopic knee surgery or simultaneous 
cruciate ligament reconstruction or microfracture in the 
same knee were excluded.
Outcomes Patients subsequently undergoing a knee 
arthroplasty in the same knee were identified and 
mortality- adjusted survival analysis was performed 
(survival without undergoing knee arthroplasty). A Cox 
proportional hazards model was used to identify factors 
associated with knee arthroplasty. Relative risk of knee 
arthroplasty (total or partial) in comparison to the general 
population was determined.
results Through 2007 to 2017, 157 730 eligible 
chondroplasty patients were identified. Within 1 year, 
5.91% (7984/135 197; 95% CI 5.78 to 6.03) underwent 
knee arthroplasty and 14.22% (8145/57 267; 95% CI 13.94 
to 14.51) within 5 years. Patients aged over 30 years with a 
history of chondroplasty were 17.32 times (risk ratio; 95% 
CI 16.81 to 17.84) more likely to undergo arthroplasty than 
the general population without a history of chondroplasty.
Conclusions Patients with cartilage lesions of the 
knee, treated with arthroscopic chondroplasty, are at 
greater risk of subsequent knee arthroplasty than the 
general population and for a proportion of patients, 
there is insufficient benefit to prevent the need for knee 
arthroplasty within 1 to 5 years. These important new data 
will inform patients of the anticipated outcomes following 
this procedure. The risk in comparison to non- operative 
treatment remains unknown and there is an urgent need 
for a randomised clinical trial in this population.
IntrODuCtIOn
Around 2 million knee arthroscopy proce-
dures are performed worldwide each year.1 
Historically, knee washout and ‘debridement’ 
was shown to be ineffective for the treatment 
of advanced osteoarthritis.2–4 For early osteo-
arthritis, however, a number of surgical and 
non- surgical treatments are available and 
treatment selection is challenging.5 The aim 
of treatment in these cases is to improve 
symptoms and delay or prevent progressive 
osteoarthritis.6
Chondroplasty is a non- specific term that 
encompasses several techniques for the 
treatment of cartilage defects.7 It includes 
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debridement and abrasion using mechanical ‘shavers’ 
and, more recently, thermal or radiofrequency tech-
niques have also emerged despite some concerns these 
techniques might risk inducing localised chondrocyte 
death.7–11 Recent national guidance was cautiously 
supportive of radiofrequency chondroplasty for the treat-
ment of ‘discrete chondral defects’ based on a small 
number of clinical trials comparing the outcomes of 
mechanical and radiofrequency techniques.12 It is not 
known which patients are most likely to benefit from 
chondroplasty procedures and when the procedure does 
not provide sustained benefit, knee arthroplasty is often 
indicated. The success rate of chondroplasty is, however, 
poorly understood and the proportion of patients under-
going subsequent knee arthroplasty after this interven-
tion has been unknown.
The purpose of this study was to determine the propor-
tion of patients undergoing knee chondroplasty proce-
dures that subsequently receive a knee arthroplasty in 
the same knee, with specific focus on the proportion of 
patients undergoing early arthroplasty with 1 year or 2 
years of chondroplasty. Factors associated with the risk of 
subsequent arthroplasty are reported and the relative risk 
in comparison to the general population determined.
MethODS
Data source
National Hospital Episode Statistics (HES) data was 
obtained (application DARS- NIC-68703) in a de- identi-
fied (pseudoanonymised) format from National Health 
Service (NHS) Digital.13 HES contains a record of de- iden-
tified patient attendances at NHS hospitals in England.13 
The data is submitted by hospitals to claim payment 
for the services they provide and is also intended for 
secondary use, including research. HES includes episodes 
of care delivered in treatment centres (including those 
in the independent sector) funded by the NHS, episodes 
of care in England where patients are resident outside 
of England and privately funded patients treated within 
NHS England hospitals. The information recorded in 
the HES database includes patient demographic and resi-
dence data, primary and secondary diagnoses including 
comorbidities, and all procedures undertaken.
Procedures
All HES records between 1 April 2007 and 31 March 2017 
were extracted for patients undergoing arthroscopic chon-
droplasty. Patients undergoing previous arthroscopic knee 
surgery or simultaneous cruciate ligament reconstruction 
or microfracture in the same knee were excluded. Proce-
dures were identified using the Classification of Surgical 
Operations and Procedures (OPCS-4) codes recorded 
within the HES data (see online supplementary appendix 
1 for OPCS-4 code list).14 All knee arthroplasty (partial 
or total) procedures were also identified (online supple-
mentary appendix 2) for the whole population to enable 
the relative risk of knee arthroplasty with and without a 
history of chondroplasty to be determined.
Outcomes
The primary outcome was knee arthroplasty, matched to 
the side of any previous chondroplasty (using recorded 
OPCS-4 laterality codes).
Statistical analysis
Stata V.15.1 (StataCorp, College Station, Texas, USA) was 
used to perform all analysis. In accordance with Office 
for National Statistics (ONS) and NHS Digital guidance, 
rates where the number of events was less than six were 
suppressed.15 Procedures with date errors or missing 
laterality were excluded. The absolute rate of knee 
arthroplasty was determined at 1 year, 2 years, 5 years 
and 8 years following arthroscopic chondroplasty as the 
proportion of the cohort with this minimum period of 
follow- up. Mortality adjusted Kaplan- Meier survival anal-
ysis (survival was defined as not undergoing knee arthro-
plasty) was also performed and stratified by patient age 
group and sex.
A Cox proportional hazards model was used first to 
calculate the unadjusted HR of knee arthroplasty over time 
by age group, sex, index of multiple deprivation (quin-
tile derived from regional factors in England including 
average income, employment, education, housing and 
crime; 1=least deprived area, 5=most deprived), ethnicity, 
modified Charlson comorbidity index (derived with 
maximum 5- year diagnosis code lookback period),16–18 
year of treatment (chondroplasty), rurality and ethnicity, 
respectively.16–19 The HRs were then adjusted including 
all these variables in the model.
The relative risk (risk ratio) of knee arthroplasty in the 
population of patients with a history of chondroplasty in 
comparison to the general population (without a history 
of chondroplasty) was estimated for the year 2016 to 2017. 
All patients undergoing knee arthroplasty in 2016 to 2017 
were identified and the number of these patients with a 
recorded previous chondroplasty (in the prior 10 years 
of HES data), versus those without, made up the numer-
ator for each respective population. The chondroplasty 
population denominator was the number of patients with 
a history of chondroplasty that had not undergone a knee 
arthroplasty prior to 2016 to 2017. The denominator for 
the non- chondroplasty population was the ONS mid- year 
population estimate less the chondroplasty population.
Patient and public involvement
There was no patient and public involvement in this study.
reSultS
Over the study period, 157 730 chondroplasty patients 
were identified as eligible for analysis (figure 1). The 
mean age of the chondroplasty cohort was 51.7 year (SD 
13.8) and 48.1% were female (table 1). Over the same 
period, 604 056 patients underwent knee arthroplasty, of 
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Figure 1 Flow chart illustrating extraction of patient level 
cohort.
which 35 916 (5.95%) had a record of a previous chon-
droplasty (table 1).
Overall, following chondroplasty, 5.91% (7984/135 
197; 95% CI 5.78 to 6.03) patients underwent knee arthro-
plasty within 1 year, 9.41% (10 787/114 592; 95% CI 9.24 
to 9.58) within 2 years, 14.22% (8145/57 267; 95% CI 
13.94 to 14.51) within 5 years and 17.61% (2879/16 347; 
95% CI 17.03 to 18.20) within 8 years (table 2). The risk 
of arthroplasty was greater in female patients (adjusted 
HR 1.38; 95% CI 1.34 to 1.42) and in older patients 
(adjusted HR 1.33 per 5 years; 95% CI 1.32 to 1.34) 
(table 3, figure 2; figure 3). Patients with a greater comor-
bidity index were also at increased risk of subsequently 
undergoing arthroplasty (adjusted HR 1.03 per five units 
Charlson index; 95% CI 1.01 to 1.05).
The risk of knee arthroplasty after chondroplasty fell 
slightly over time, by year of chondroplasty treatment 
(adjusted HR 0.95 per 5 years; 95% CI 0.92 to 0.98). 
Patients in regions of increased deprivation and patients 
of white ethnicity were at greater risk of subsequent 
arthroplasty (table 2). Patients undergoing concurrent 
meniscal surgery were also at greater risk of subsequent 
arthroplasty (adjusted HR 1.09; 95% CI 1.06 to 1.13).
In 2016 to 2017, the rate of knee arthroplasty was 3.49% 
(95% CI 3.39 to 3.60) in patients (aged 30 or older) with 
a recorded history of chondroplasty and 0.20% (95% CI 
0.19 to 0.20) in patients without a record of chondro-
plasty. This corresponded to an overall relative risk of 
knee arthroplasty for the chondroplasty cohort patients 
of 17.32 times (risk ratio (RR); 95% CI 16.81 to 17.84) 
that of the general population (table 4).
Although the absolute annual rate of knee arthroplasty 
was low, the relative risk of undergoing knee arthroplasty 
at a younger age was greatly elevated in comparison to 
arthroplasty at an older age, as shown in table 4. Patients 
aged 30 to 39 with a history of a previous chondroplasty 
were 170.92 times (RR; 95% CI 116.72 to 250.30) more 
likely to undergo knee arthroplasty than the general 
population, per year, in comparison to 11.09 times (RR; 
95% CI 10.42 to 11.80) more likely for the over 69 age 
group.
DISCuSSIOn
Principal findings
Patients undergoing chondroplasty procedures of the 
knee have a 17 times increased risk of receiving a knee 
arthroplasty compared with the general population. 
Nearly 10% of patients will have received a knee arthro-
plasty within 2 years of the chondroplasty procedure. The 
relative risk of undergoing arthroplasty at a young age 
is particularly elevated, reaching 171 times the general 
population rate for arthroplasty between the ages of 30 
and 39 years of age. For a proportion of patients, the 
results indicate insufficient benefit to prevent the need 
for knee arthroplasty within 1 or 2 years, but the risk had 
these patients not undergone chondroplasty remains 
unknown.
Comparison to other studies
We previously reported trends in chondroplasty surgery 
in England, but data from other countries is not avail-
able.20 The age- sex standardised rate of chondroplasty 
increased 191% from 17.6/100 000 (95% CI 17.2 to 
18.0) in 2007/2008 to 51.2/100 000 (95% CI 50.6 to 
51.7) in 2016/2017.20 The rate of chondroplasty was 
greatest in patients aged 40 to 59 years (increasing 210% 
from 34.3/100 000 in 2007/2008 to 106.4/100 000 in 
2016/2017.20
In England, although national guidance has been 
cautiously supportive of radiofrequency chondroplasty 
for specific indications, there is only limited evidence 
demonstrating the effectiveness of chondroplasty 
compared with alternative surgical or non- surgical treat-
ments.12 The only randomised studies have been limited 
to comparisons of different chondroplasty techniques.10 12 
Long- term outcomes following chondroplasty have yet to 
be reported.12
Older patients are much more likely to have generalised 
osteoarthritis, rather than ‘discrete chondral defects’ for 
which the national guidance supports radiofrequency 
chondroplasty.12 21 For more generalised osteoarthritis, 
chondroplasty is analogous to debridement and washout, 
where multiple clinical trials demonstrate no benefit.2–4 
The use of chondroplasty in the treatment of patients 
with more generalised chondral pathology is therefore 
unproven and not recommended.22 In our study, there 
was considerable age- group variation in outcomes, with 
18.8% of patients aged 60 to 79 years undergoing arthro-
plasty within 2 years of chondroplasty, in comparison to 
0.43% for patients undergoing chondroplasty aged 20 to 
39 years. This observation is consistent with the presence 
of more established osteoarthritis in older age groups.
Female patients were observed to be of greater risk of 
subsequent arthroplasty in our study. This has previously 
been observed following knee arthroscopy in the USA.23 
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Table 1 Demographics and descriptive statistics of cohort
Chondroplasty cohort Knee arthroplasty cohort
All cases No previous chondroplasty Previous chondroplasty
n % n % n %
Total 157 730 100.00 568 140 94.05 35 916 5.95
Sex
  Male 81 884 51.91 244 684 43.07 15 512 43.19
  Female 75 846 48.09 323 456 56.93 20 404 56.81
Age group (years)
  <20 2868 1.82 1179 0.21 1 <0.01
  20–39 24 648 15.63 1568 0.28 353 0.98
  40–59 83 258 52.79 85 797 15.1 14 023 39.04
  60–79 45 191 28.65 400 541 70.5 20 361 56.69
  80+ 1765 1.12 79 055 13.91 1178 3.28
Charlson comorbidity index
  0 121 605 77.10 534 399 94.06 27 331 76.1
  1–15 34 719 22.01 31 683 5.58 8175 22.76
  16–30 1296 0.82 1879 0.33 393 1.09
  31–50 110 0.07 179 0.03 17 0.05
Index of multiple deprivation (quintiles)
  1=least deprived 36 043 23.21 121 813 21.44 7921 22.05
  2 35 189 22.66 127 672 22.47 7938 22.1
  3 32 493 20.92 123 160 21.68 7806 21.73
  4 27 312 17.59 103 236 18.17 6372 17.74
  5=most deprived 24 266 15.62 85 283 15.01 5416 15.08
  Missing 2427 6976 463
Rurality
  Urban 119 766 76.42 423 895 74.61 27 157 75.61
  Rural 36 953 23.58 141 271 24.87 8634 24.04
  Missing 1011 2974 125
Ethnicity
  White 141 928 94.43 525 934 92.57 34 349 95.64
  Mixed 953 0.63 1844 0.32 115 0.32
  Asian 4511 3.00 19 203 3.38 804 2.24
  Black 2122 1.41 5840 1.03 193 0.54
  Other 792 0.53 1367 0.24 68 0.19
  Missing 7424 13 952 387
Concurrent procedures
  None 65 987 41.84 – – – –
  Meniscal 91 743 58.16 – – – –
Patients of white ethnicity and greater deprivation were 
also at greater risk in our cohort. These findings may 
reflect differences in healthcare access including treat-
ment thresholds for either the chondroplasty or knee 
arthroplasty, or differences in care seeking behaviour 
which has been shown to be influenced by socioeconomic, 
cultural, occupational and psychological factors, or there 
could be biological factors underlying the observation.24–26 
Patients with a greater comorbidity index were more likely 
to undergo subsequent arthroplasty, and the reason for 
this is unclear. One possible explanation might be an asso-
ciation between comorbidity and higher body mass index 
(BMI), which is not recorded in this data set, with patients 
having a greater BMI being more likely to progress to end- 
stage osteoarthritis, or that these patients had more severe 
pathology at the time of their index chondroplasty.27 
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Table 3 Unadjusted and adjusted* risk of knee arthroplasty 
following arthroscopic chondroplasty
Unadjusted risk 
subsequent TKA
Adjusted risk 
subsequent TKA
HR 95% CI HR 95% CI
Sex
  Male 1.00 1.00 1.00 1.00
  Female 1.61 1.57 to 1.66 1.38 1.34 to 1.42
Age (per 5 years)
  Per year 1.35 1.35 to 1.36 1.33 1.32 to 1.34
Year of treatment (per 5 years)
  Year 0.99 0.96 to 1.03 0.95 0.92 to 0.98
Charlson comorbidity index (per five units)
  Charlson 
index
1.29 1.27 to 1.31 1.03 1.01 to 1.05
Index of multiple deprivation (quintile)
  1=least 1.00 1.00 1.00 1.00
  2 1.03 0.99 to 1.08 1.07 1.03 to 1.12
  3 1.08 1.04 to 1.13 1.17 1.12 to 1.22
  4 1.03 0.99 to 1.08 1.20 1.15 to 1.26
  5=most 1.01 0.96 to 1.06 1.29 1.23 to 1.36
Rurality
  Urban 1.00 1.00 1.00 1.00
  Rural 1.03 1.00 to 1.07 0.99 0.95 to 1.02
Ethnicity
  White 1.00 1.00 1.00 1.00
  Mixed 0.50 0.38 to 0.65 0.66 0.51 to 0.86
  Asian 0.65 0.59 to 0.72 0.73 0.66 to 0.81
  Black 0.35 0.28 to 0.42 0.44 0.36 to 0.54
  Other 0.34 0.24 to 0.48 0.45 0.32 to 0.64
Concurrent procedures
  None 1.00 1.00 1.00 1.00
  Meniscal 
surgery
1.52 1.48 to 1.57 1.09 1.06 to 1.13
*Adjusted by all variables in the table.
†Age <20 years suppressed due to small numbers.
TKA, total or partial knee arthroplasty.
Figure 2 Survival curve (not undergoing knee arthroplasty) 
following chondroplasty by age+ 
Age groups < 20 years and 80+ years suppressed due to 
small numbers
Figure 3 Survival curve (not undergoing knee arthroplasty) 
following chondroplasty by sex. 
Age groups < 20 years and 80+ years suppressed due to 
small numbers 
Patients undergoing concurrent meniscal surgery were 
also more likely to undergo subsequent arthroplasty, 
which is expected given the association between meniscal 
injury, osteoarthritis and knee arthroplasty.28
Recently, there has been renewed focus on the impor-
tance of and requirements for individualised patient 
consent.29 Our findings make an important contribution 
to the current evidence, and patients can now be appro-
priately counselled and consented with knowledge of 
anticipated long- term outcomes.
Strength and limitations
A key strength of our study is the identification of all knee 
chondroplasty procedures performed in the National 
Health Service over a 10- year period, creating the largest 
reported cohort of patients receiving this procedure. 
Patients with a history of prior arthroscopy in the same 
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Table 4 Rates and relative risk of undergoing TKA with previous chondroplasty by age at TKA in 2016 to 2017
Age at TKA 
(years)
Prior chondroplasty Without prior chondroplasty Relative risk
Annual rate 
TKA/100 k 95% CI
Annual rate 
TKA/100 k 95% CI RR 95% CI
30–39 274.48
(0.27%)
190.16 to 383.35
(0.19% to 0.38%)
1.60
(0.00%)
1.32 to 1.92
(0.00% to 0.00%)
170.92 116.72 to 250.30
40–49 1454.02
(1.45%)
1318.04 to 1600.06
(1.32% to 1.60%)
19.79
(0.02%)
18.79 to 20.82
(0.02% to 0.02%)
72.45 65.00 to 80.76
50–59 3626.62
(3.63%)
3448.20 to 3811.60
(3.45% to 3.81%)
130.68
(0.13%)
128.05 to 133.35
(0.13% to 0.13%)
26.82 25.41 to 28.30
60–69 5179.17
(5.18%)
4933.67 to 5433.20
(4.93% to 5.43%)
386.68
(0.39%)
381.64 to 391.77
(0.38% to 0.39%)
12.78 12.16 to 13.44
70+ 6090.50
(6.09%)
5721.53 to 6475.82
(5.72% to 6.48%)
520.46
(0.52%)
514.89 to 526.07
(0.51% to 0.53%)
11.09 10.42 to 11.80
Overall
(30+)
3494.61
(3.49%)
3394.82 to 3596.52
(3.39% to 3.60%)
195.38
(0.20%)
193.90 to 196.87
(0.19% to 0.20%)
17.32 16.81 to 17.84
TKA, total or partial knee arthroplasty; RR, risk ratio.
knee, simultaneous ligament reconstruction or microf-
racture were excluded as potential confounding factors. 
It should still be noted that patients undergoing non- 
NHS treatment, for example, knee arthroplasty in the 
private sector after a previous knee arthroscopy under 
NHS care, would not be captured in this data set and the 
number of these procedures performed in the private 
sector is currently unknown. National data does indi-
cate, however, that private healthcare expenditure as a 
proportion of total healthcare expenditure has remained 
relatively stable at around 17% to 18% of total health 
expenditure between 2005 and 2015.30 For all observa-
tional studies utilising large data sets there may be some 
concerns raised about coding accuracy. The data in our 
study was cleaned prior to analysis, excluding patients 
where procedures were missing the side of interven-
tion and cases where date coding errors were identified. 
Although some other data coding errors are inevitable, 
data errors in procedure coding would result in hospitals 
not receiving payment for surgery performed, and this 
provides a strong incentive for data accuracy with regards 
to the coding data analysed in this study.
We were able to stratify risk of arthroplasty by a large 
number of patient factors, but certain procedure specific 
data is not recorded. Operative factors, such as the 
affected compartment of the knee and extent of initial 
cartilage damage before intervention, are not recorded 
in this database. These factors may be important in 
determining outcome, for example, there are likely to 
be differences in long- term outcomes between chondro-
plasty performed to the tibiofemoral joint in comparison 
to the patellofemoral joint.31 Other unmeasured sources 
of potential confounding include BMI, leg alignment 
and radiographic status at the time of intervention. 
These are important considerations when considering 
if a patient is suitable for chondral surgery intervention, 
but the specific impact of these factors on long- term 
outcomes in this population remains uncertain. Subjec-
tive, patient- reported, symptomatic outcome data is not 
yet available for this cohort and radiographic outcomes 
are not recorded in the HES database. Instead, our 
study focussed on the objective, measurable outcome 
of knee arthroplasty, matched to the same knee as the 
previous chondroplasty surgery intervention. Although 
knee arthroplasty represents the end- stage of symptom-
atic failure for patients with osteoarthritis, it is likely 
to considerably underestimate the overall health and 
symptom burden in this cohort. Patients, particularly 
younger patients, may not have been willing or suitable 
candidates for knee arthroplasty, and the threshold for 
arthroplasty may have been much higher for younger age 
groups or older patients with multiple comorbidities. It is 
also important to note that, in general, ‘chondroplasty’ is 
a non- specific term that encompasses several techniques 
for the debridement of cartilage defects.7 The findings 
in this paper cannot be generalised to other types of 
arthroscopic and joint preservation surgery, cartilage 
repair and regeneration techniques, such as microfrac-
ture and autologous chondrocyte implantation.6 31
Our study represents a high- risk cohort of patients with 
cartilage damage. It is unknown from this observational 
data whether undergoing the chondroplasty procedure 
was beneficial to the symptoms or prognosis of these 
individuals over the full study period. That is, it is not 
known whether the chondroplasty procedure delayed 
or prevented arthroplasty in those patients that did not 
undergo arthroplasty (approximately 86% by 5 years), 
in which case delivery of the intervention may have been 
cost- effective, or the converse interpretation is that the 
procedure may have been overused and that the natural 
history of symptomatic osteoarthritis in this population 
was unaltered. For example, the observed proportion 
of patients undergoing arthroplasty within 1 year of 
their arthroscopic chondroplasty (6%) is suggestive of 
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suboptimal treatment selection. These individuals are 
highly unlikely to have had only localised or partial thick-
ness lesions and our results may indicate that knee arthro-
plasty may have been a more appropriate treatment. 
Nevertheless, the symptomatic outcome in the patients 
that did not undergo arthroplasty is not known and the 
answer to whether the procedure is cost- effective with 
optimal patient selection is unknown and requires eval-
uation in a high- quality randomised controlled trial with 
a non- operative treatment arm. Such a trial should help 
to evaluate the optimal indications for chondroplasty, 
assess the relative rate of progression of treated chondral 
damage with versus without chondroplasty and ultimately 
determine whether appropriate use of chondroplasty is 
beneficial to patient outcome including, potentially, the 
long- term demand for knee arthroplasty.
Our study reports the long- term outcomes following 
chondroplasty in a high- risk cohort of patients with carti-
lage damage for the first time. Our findings stratified by 
a range of patient- specific factors however further work is 
required to optimise treatment selection and additional 
patient information may allow more accurate prediction 
of outcome and guide clinical management.
COnCluSIOn
The risk of knee arthroplasty is 17 times greater in patients 
with a history of knee chondroplasty and in a propor-
tion of patients, there is insufficient benefit to prevent 
the need for knee arthroplasty within 1 or 2 years. These 
important new data help inform patients and clinicians 
of the long- term outcomes following this procedure, at 
the population level, for the first time. Enhanced clinical 
guidance on the appropriate indications for chondro-
plasty are required and there is a need for high- quality 
randomised studies to determine the relative clinical and 
cost- effectiveness of this intervention in comparison to 
alternative, including non- surgical, treatments.
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